Arvinas (ARVN) Net Income towards Common Stockholders (2017 - 2026)
Arvinas (ARVN) posted quarterly Net Income towards Common Stockholders of -$57.6 million for Q1 2026, down 169.48% year-over-year from $82.9 million in Q1 2025, and up 14.54% quarter-over-quarter from -$67.4 million in Q4 2025.
Analysis
Arvinas (ARVN) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Arvinas' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 169.48% year-over-year to -$57.6 million; the TTM figure through Mar 2026 stood at -$221.3 million (down 374.89% YoY), while the FY2025 annual figure was -$80.8 million, up 59.38% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$57.6 million, up from -$67.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $82.9 million in Q1 2025, with the low at -$154.8 million in Q4 2023.
- The 5-year median for Net Income towards Common Stockholders is -$63.3 million (2022), against an average of -$57.3 million.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders surged 219.45% in 2025, then plunged 169.48% in 2026.
- Arvinas' Net Income towards Common Stockholders stood at -$80.1 million in 2022, then tumbled by 93.26% to -$154.8 million in 2023, then soared by 70.87% to -$45.1 million in 2024, then sank by 49.45% to -$67.4 million in 2025, then gained by 14.54% to -$57.6 million in 2026.
- Business Quant data shows ARVN's Net Income towards Common Stockholders at -$57.6 million in Q1 2026, -$67.4 million in Q4 2025, and -$35.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - | 169.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 169.40 Mn |
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -63.90 Mn |
| Jun 30, 2023 | -65.30 Mn |
| Mar 31, 2023 | -80.80 Mn |
| Dec 31, 2022 | -80.10 Mn |
| Sep 30, 2022 | -63.30 Mn |
| Jun 30, 2022 | -67.50 Mn |
| Mar 31, 2022 | -61.10 Mn |
| Dec 31, 2021 | -46.10 Mn |
| Sep 30, 2021 | -46.80 Mn |